Perfluorocarbon Nanoemulsions Enhance Therapeutic siRNA Delivery in the Treatment of Pulmonary Fibrosis

Adv Sci (Weinh). 2022 Mar;9(8):e2103676. doi: 10.1002/advs.202103676. Epub 2022 Jan 7.

Abstract

Local pulmonary administration of therapeutic siRNA represents a promising approach to the treatment of lung fibrosis, which is currently hampered by inefficient delivery. Development of perfluorooctylbromide (PFOB) nanoemulsions as a way of improving the efficiency of pulmonary polycation-based delivery of siRNA is reported. The results show that the polycation/siRNA/PFOB nanoemulsions are capable of efficiently silencing the expression of STAT3 and inhibiting chemokine receptor CXCR4-two validated targets in pulmonary fibrosis. Both in vitro and in vivo results demonstrate that the nanoemulsions improve mucus penetration and facilitate effective cellular delivery of siRNA. Pulmonary treatment of mice with bleomycin-induced pulmonary fibrosis shows strong inhibition of the progression of the disease and significant prolongation of animal survival. Overall, the study points to a promising local treatment strategy of pulmonary fibrosis.

Keywords: CXCR4; STAT3; idiopathic pulmonary fibrosis; perfluorocarbon emulsion; pulmonary siRNA delivery.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Bleomycin / adverse effects
  • Bleomycin / metabolism
  • Fluorocarbons* / adverse effects
  • Fluorocarbons* / metabolism
  • Lung / metabolism
  • Lung / pathology
  • Mice
  • Pulmonary Fibrosis* / chemically induced
  • Pulmonary Fibrosis* / genetics
  • Pulmonary Fibrosis* / therapy
  • RNA, Small Interfering / genetics
  • RNA, Small Interfering / metabolism
  • RNA, Small Interfering / pharmacology

Substances

  • Fluorocarbons
  • RNA, Small Interfering
  • Bleomycin